3. >>Biosimilars

Pfizer Receives CHMP Backing On EU Bevacizumab And Withdraws Skinny Label Adalimumab UPDATED

 
• By Dean Rudge

Pfizer was at the forefront of the CHMP’s December 2018 meeting concerning biosimilars, while Dipharma and PARI Pharma were backed on a generic and hybrid medicine apiece.

Capsule
CHMP backs a biosimilar, a generic and a hybrid medicine apiece • Source: Shutterstock

Pfizer has been backed to receive a European Union- (EU-) wide marketing authorization approval for the firm’s Avastin (bevacizumab) biosimilar but has also shelved one of its two Humira (adalimumab) biosimilar applications, a 'limited label' filing with indications carved out, for strategic reasons.

During the December meeting of the European Medicines Agency's (EMA’s) Committee for Medicinal Products for Human Use (CHMP), the committee adopted a positive opinion recommending the granting

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products